3 results on '"Romagno, D"'
Search Results
2. Hepatitis C in the elderly: a multicentre cross-sectional study by the Italian Association for the Study of the Liver
- Author
-
Gramenzi, A, Conti, F, Cammà, C, Grieco, A, Picciotto, A, Furlan, C, Romagno, D, Costa, P, Rendina, M, Ancarani, F, Chiaramonte, Maria, Verucchi, G, Craxì, A, Bernardi, M, Andreone, P, Floreani, Annarosa, Basso, Monica, Gramenzi, A, Conti, F, Cammà, C, Grieco, A, Picciotto, A, Furlan, C, Romagno, D, Costa, P, Rendina, M, Ancarani, F, Chiaramonte, M, Verucchi, G, Craxi, A, Bernardi, M, Andreone, P, Gramenzi A, Conti F, Cammà C, Grieco A, Picciotto A, Furlan C, Romagno D, Rendina M, Chiaramonte M, Verucchi G, Craxi A, Bernardi M, and Andreone P.
- Subjects
Liver Cirrhosis ,Male ,AGED PATIENTS ,EPIDEMIOLOGY ,HCV INFECTION ,LIVER DISEASES ,ANTI-VIRAL TREATMENT ,Epidemiology ,Cross-sectional study ,Hepacivirus ,medicine.disease_cause ,Liver disease ,80 and over ,Prevalence ,Chronic ,Aged patients ,Aged, 80 and over ,education.field_of_study ,hepatitis c elderly italy ,Age Factors ,Gastroenterology ,liver diseases ,hcv infection ,epidemiology ,aged patients ,Alanine Transaminase ,Hepatitis C ,Viral Load ,HCV infection ,Italy ,HCV ,Liver diseases ,Population study ,Female ,Viral load ,medicine.medical_specialty ,Genotype ,Settore MED/12 - GASTROENTEROLOGIA ,Hepatitis C virus ,Population ,geriatric ,Antiviral Agents ,Internal medicine ,medicine ,Humans ,education ,Settore MED/42 - IGIENE GENERALE E APPLICATA ,Aged ,Hepatology ,business.industry ,Settore MED/09 - MEDICINA INTERNA ,Hepatitis C, Chronic ,Hepatitis C Antibodies ,medicine.disease ,Surgery ,Cross-Sectional Studies ,business - Abstract
Background: The prevalence of hepatitis C virus infection increases with advancing age, but elderly hepatitis C virus patients remain an understudied population. Aim: To define the virological, epidemiological and clinical profiles of Italian outpatients aged 65 years and over infected by hepatitis C virus. Methods: We evaluated 1544 anti-hepatitis C virus positive patients aged >=65 years referred to 34 Italian outpatient specialty clinics over a two-year period. Results: The study population included 1134 (73%) early elderly (65-74 years) and 410 (27%) late elderly patients (>=75 years). Late elderly subjects were less likely to have their virus genotyped, their viral load assessed or a histological evaluation of liver disease. Overall, 30% of patients had advanced liver disease whose prevalence increased with increasing age. In both age groups, about 40% of patients had normal transaminase levels. Excluding patients with past infection, 51% had not received any antiviral treatment and only 25% were treated after the age of 65. Late elderly patients, women and patients with advanced liver diseases had been less frequently treated. The main reason for exclusion from treatment was age followed by the presence of comorbid conditions. Conclusions: Elderly hepatitis C virus patients referred to Italian specialty clinics have advanced and underestimated liver disease. Nevertheless, they are progressively understudied in parallel with increasing age. © 2012 Editrice Gastroenterologica Italiana S.r.l.
- Published
- 2012
- Full Text
- View/download PDF
3. Pegylated interferon α plus ribavirin for the treatment of chronic hepatitis C: A multicentre independent study supported by the Italian Drug Agency
- Author
-
Rosina, Floriano, Tosti, Maria Elena, Borghesio, Elisabetta, Masocco, Maria, Mele, Alfonso, Coppola, Carmine, Milella, Michele, Borgia, Guglielmo, Andreone, Pietro, Koch, Maurizio, Zignego, Anna Linda, Romano, Mario, Carrara, Maurizio, Almasio, Piero Luigi, Azzola, Emilio, Nardone, Gerardo, Benedetti, Antonio, Carosi, Giampiero, Mazzotta, Francesco, Sagnelli, Evangelista, Rizzetto, Mario, Mascolo, M. C., Cursaro, C., Scuteri, A., Crespi, C., Gianstefani, A., Ranieri, J., Monti, M., Corti, G., Blanc, P. L., Baragli, F., Bellentani, S., Gasbarrini, A., Pompili, M., Mecenate, F., Picardi, A., Vespasiani, U., Nosotti, Null, Null, A. Picardi, Ricci, G. L., Paffetti, A., Mastropietro, C., Moretti, A., Spagnolo, A. L., Puoti, C., Bellis, L., Regazzetti, A., Maffezzini, E., Pietrangelo, A., Abbati, G., Borghi, A., Sardini, C., Raimondo, G., Scribano, L., Martines, D., Svegliati Baroni, G., Faraci, G., Schi anchi, S., Fornaciari, G., Massari, M., Fabris, P., Bertin, T., Salvagnini, M., Madonia, S., Calì, A., Civitavecchia, G., Pirisi, M., Smirne, C., Andreoletti, M., Morisco, F., Caporaso, N., Gentile, I., Brancaccio, G., Gaeta, G. B., Liberti, A., Iannece, M. D., Rocco, A., Federico, A., Loguercio, C., Riegler, G., Esposito, P., Fargion, S., Fatta, E., Masutti, F., Bonaventura, M. E., Autolitano, A., Russello, M., Bellia, A., Toniutto, P., Bitetto, D., Pasulo, L., Lucà, M. G., Grattagliano, I., Palasciano, G., Romagno, D., Giannelli, G., Napoli, N., Plattella, M. S., Cassano, P., Gobbo, G., Monti, V., Raspanti, A., Cuccorese, Null, Colombo, A. E., Mandelli, G., Spinzi, G. C., Floridia, Null, Messina, V., Bonfante, S., Bellissima, P., Toti, M., Vecchiet, J., Falasca, K., Portelli, V., Stefano, G. De, Pietromatera, G., Viganò, P., Re, T., Andreoni, M., Null, G. Raineri, Grossi, P. A., Caputo, S., Cassola, G., Feasi, M., Biagio, A. Di, Nicolini, LAURA AMBRA, Giannini, EDOARDO GIOVANNI, Corbo, M., Foti, G., Kunkar, A., Caterini, L., Migliorini, D., Chiodera, A., Calleri, G., Spezia, C., Framarin, L., Null, M. Berrutti, Ciancio, A., Baiguera, C., Puoti, M., Vento, S., Contini, C., Boccia, S., Casiraghi, M. A., Simone, L., Tacconi, D., Caremani, M., Almi, P., Chimenti, M., Cosco, Null, Messeri, D., Esperti, F. C., Lomonaco, L., Pazzi, P., Fornari, F., Comparato, G., Casetti, T., Foschi, F. G., Samori, A., Ferretti, E., Marin, R., Campo, N., Testa, R., Rizzo, S., Rosina, F, Tosti, ME, Borghesio, E, Masocco, M, Mele, A, Coppola, C, Milella, M, Borgia, G, Andreone, P, Koch, M, Zignego, AL, Romano, M, Carrara, M, Almasio, PL, Azzola, E, Nardone, G, Benedetti, A, Carosi, G, Mazzotta, F, Sagnelli, E, Rizzetto, M, Rosina, F., Tosti, M. E., Borghesio, E., Masocco, M., Mele, A., Coppola, C., Milella, M., Borgia, Guglielmo, Andreone, P., Koch, M., Zignego, A. L., Romano, M., Carrara, M., Almasio, P. L., Azzola, E., Nardone, GERARDO ANTONIO PIO, Benedetti, A., Carosi, G., Mazzotta, F., Sagnelli, E., Rizzetto, M., Aifa, Aisf, Simit, Aigo, Sige, Gentile, Ivan, Morisco, Filomena, Et, Al, Floriano Rosina, Maria Elena Tosti, Elisabetta Borghesio, Maria Masocco, Alfonso Mele, Carmine Coppola, Michele Milella, Guglielmo Borgia, Pietro Andreone, Maurizio Koch, Anna Linda Zignego, Mario Romano, Maurizio Carrara, Piero Luigi Almasio, Emilio Azzola, Gerardo Nardone, Antonio Benedetti, Giampiero Carosi, Francesco Mazzotta, Evangelista Sagnelli, and Mario Rizzetto
- Subjects
Registrie ,Male ,Cirrhosis ,medicine.disease_cause ,Polyethylene Glycol ,Gastroenterology ,Polyethylene Glycols ,chemistry.chemical_compound ,Hepatitis Viruses ,Hepatitis Viruse ,Prospective Studies ,Viral ,Registries ,Chronic ,Prospective cohort study ,Drug Carrier ,Drug Carriers ,Settore MED/12 - Gastroenterologia ,Medicine (all) ,Recombinant Protein ,Middle Aged ,Hepatitis C ,Recombinant Proteins ,Treatment Outcome ,Italy ,Combination ,RNA, Viral ,Population study ,Drug Therapy, Combination ,Female ,Human ,medicine.medical_specialty ,Genotype ,Hepatitis C virus ,Alpha interferon ,Ribavirin ,Sustained virological response (SVR) ,Treatment ,Antiviral Agents ,Follow-Up Studie ,Hepatology ,Drug Therapy ,Internal medicine ,medicine ,Humans ,Antiviral Agent ,business.industry ,Interferon-alpha ,HCV therapy ,Hepatitis C, Chronic ,medicine.disease ,Clinical trial ,Prospective Studie ,chemistry ,Immunology ,RNA ,Follow-Up Studies ,business - Abstract
a b s t r a c t Background: Data on the efficacy of Peg-interferon/ribavirin therapy for chronic hepatitis C are mostly derived from treatment of selected patients enrolled in clinical trials. This study aimed to assess the effectiveness of Peg-interferon/ribavirin therapy in “real world” chronic hepatitis C patients in Italy. Methods: Independent observational multicentre study including consecutive patients receiving Peginterferon/ribavirin in the 18 months before (retrospective phase) and after (prospective phase) the start of the study. Results: 4176 patients were eligible. The final study population consisted of 2051 patients in the retrospective and 2073 in the prospective phase. Sustained virological response was achieved by 1036 patients (50.5%) during the retrospective phase: 325 were genotypes 1/4 (34.1%) and 684 were genotypes 2/3 (67.2%) and by 800 patients (38.6%) during the prospective phase: 300 were genotypes 1/4 (28.4%) and 473 were genotypes 2/3 (51.5%). During multivariate analysis genotypes 2/3 were significantly associated with higher sustained virological response rates; cirrhosis and -glutamil-transpeptidase >2 times the normal limit were associated with poorer response. Conclusions: The response to Peg-interferon/ribavirin therapy in “real world” clinical practice is distinctly lower than in registration trials. The difference in response rates was more pronounced among easy-totreat than among difficult-to-treat hepatitis C virus genotypes.
- Published
- 2014
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.